MARKET

ICAD

ICAD

ICAD US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.84
+0.93
+8.52%
Closed 17:26 09/23 EDT
OPEN
11.07
PREV CLOSE
10.91
HIGH
11.94
LOW
10.99
VOLUME
232.91K
TURNOVER
--
52 WEEK HIGH
21.44
52 WEEK LOW
8.48
MARKET CAP
296.42M
P/E (TTM)
-34.1309
1D
5D
1M
3M
1Y
5Y
Traders Circulate TipRanks Article 'Analysts Say 'Buy the Dip' in These 3 Stocks'
https://blog.tipranks.com/analysts-say-buy-the-dip-in-these-3-stocks-2/
Benzinga · 3d ago
Even though iCAD (NASDAQ:ICAD) has lost US$33m market cap in last 7 days, shareholders are still up 249% over 3 years
iCAD, Inc. ( NASDAQ:ICAD ) shareholders might understandably be very concerned that the share price has dropped 41% in...
Simply Wall St. · 3d ago
Director Of Icad Makes $217.70 Thousand Sale
Andy Sassine, Director at Icad (NASDAQ:ICAD), made a large insider sell on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Sassine sold 20,000 shares of Ica...
Benzinga · 09/16 15:33
iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact
Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlogNASHUA, N.H., Sept. 09, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providi...
GlobeNewswire · 09/09 18:46
4 Specialized AI Stocks to Buy for the Boom
Investor Place · 08/31 17:06
BRIEF-ICAD's Xoft Brain IORT Shows Improvement In Survival In Recurrent Glioblastoma
reuters.com · 08/31 13:33
iCAD Reports Its Xoft Brain Intraoperative Radiation Therapy Showed Improvement In Overall Survival For Patients With Recurrent Glioblastoma
Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months
Benzinga · 08/31 12:15
iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study
Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatmentNASHUA, N.H., Aug. 31, ...
GlobeNewswire · 08/31 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICAD. Analyze the recent business situations of ICAD US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICAD stock price target is 24.00 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 125
Institutional Holdings: 13.62M
% Owned: 54.39%
Shares Outstanding: 25.04M
TypeInstitutionsShares
Increased
28
754.25K
New
16
1.08M
Decreased
31
1.17M
Sold Out
13
378.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.62%
Healthcare Equipment & Supplies
+0.77%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Klein
President
Stacey Stevens
Chief Financial Officer/Secretary
Charles Carter
Chief Technology Officer
Jonathan Go
Lead Director/Independent Director
Nathaniel Dalton
Independent Director
Rakesh Patel
Independent Director
Andrew Sassine
Independent Director
Susan Wood
No Data
About ICAD
iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.